An interventional study of Alpha Auditory Entrainment and Sham in Fragile X Syndrome, Autism Spectrum Disorder and Autistic Disorder, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 1 site in United States. Open to participants aged 5 Years to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-30.
Sponsored by Children's Hospital Medical Center, Cincinnati · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Fragile X Syndrome with a site in United States — 11 open to participants now, 16 under way, 2 of them phase 3. Fragile X Syndrome · United States.
Among the 82 studies in Fragile X Syndrome with a site in United States, this one is the 8th largest by planned enrollment of the 68 interventional ones that give a count, is one of 4 that started in 2023, is one of 14 with no phase, reaches primary completion later than 9 of the 15 other live ones, and was the 74th registered.
115 studies on the registry are indexed under Fragile X Syndrome; 25 are open to participants now.
Browse Fragile X Syndrome studies →11 of the 82 studies in Fragile X Syndrome with a site in United States are open now. Recruiting first, the newest first:
Healing Hope International · Sites in United States
Ages 4–12
Mirum Pharmaceuticals, Inc. · Sites in United States, Spain
Ages 13–45 · Men only
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+ · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 6 mo–26 mo · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 24 mo–4 yrs · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Fragile X Syndrome studies recruiting now, 5 (28%) set no upper age limit and 13 (72%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.
This study: 5 Years to 10 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 36 · Phase 3 11 · Phase 4 2
First in 2002; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 54 across 92 interventional studies indexed under Fragile X Syndrome.
Median enrollment 60 across the 68 interventional studies, 100 across the 12 observational. Of the 58 that completed or were terminated, 22 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 82 have an industry lead sponsor. The 10 most frequent:
Children's Hospital Medical Center, Cincinnati is the lead sponsor of 673 studies on the registry; 129 are open to participants now.
Of its 57 completed or terminated interventional studies of FDA-regulated products, 32 (56%) have results posted.
Children's Hospital Medical Center, Cincinnati has 8 studies filed under Fragile X Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Fragile X Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05367960Phase 3Tetra Discovery PartnersAn Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome | 2027-09-30 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06139172Rush University Medical CenterWeb Intervention for Parents of Youth With Genetic Syndromes (WINGS) | 2026-12 |
| NCT06560242Children's Hospital Medical Center, CincinnatiTracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant | 2027-03-01 |
| NCT05957549Children's Hospital Medical Center, CincinnatiTracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG-Preschool Age | 2027-03-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 82 studies in Fragile X Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Fragile X Syndrome (FXS) is a complex neurodevelopmental disorder caused by a mutation on the X chromosome. Scientists have investigated FXS extensively in both humans and animals. Thus far, phenotypic rescue in animal models has not resulted in treatment breakthroughs in humans, though some important discoveries have been made. Research has shown that individuals with FXS process sounds differently than those in the typical population, and they also show baseline differences in brain activity, including high gamma activity, increased theta activity, and decreased alpha activity. The investigators' central hypothesis is that these alterations in brain activity (specifically alpha and gamma activity) impair the brain's ability to process new information, thereby impeding cognitive functioning and increasing sensory sensitivity. The investigators propose that auditory entrainment, a technique that involves playing special sounds through headphones, will normalize brain activity in individuals with FXS and lead to increased cognitive function and decreased sensory hypersensitivity.
Fragile X Syndrome (FXS) is an exemplar monogenetic neurodevelopmental disorder (NDD) where a tremendous body of multi-species translational research has elucidated the underlying molecular pathophysiology, and more recently, in-depth electrophysiology of cortical function. Thus far, phenotypic rescue in animal models has not resulted in treatment breakthroughs in humans. Central to this discrepancy is a poor understanding of the constituent neurodynamics of averaged group effects and individual variability in human brain activity as related to higher-level cognitive symptomatology and clinical phenotype. The investigators' large collection of preliminary data demonstrates that individuals with FXS do not mount precise neural responses to the sensory auditory chirp and, instead, have "noisy" asynchronous gamma activity. Furthermore, a marked reduction in alpha power suggests altered thalamocortical function, reducing the ability to detect signal from noise and representing potential tractable targets for "bottom-up" entrainment. This approach involves three scientific aims, which, if addressed, would ascertain underlying mechanisms that may alleviate sensory and cognitive impairments. First, the investigators will study transient, non-continuous features (neurodynamics) of alpha and gamma oscillations in resting-state EEG and sensory auditory chirp that model patient-level heterogeneity and constitute group effects (Aim 1A), and will also identify what, if any, of these novel features are conserved in the Fmr1-/-KO using preexisting murine EEG data and represent patient subgroups (Aim 1B). Second, the research team will extend into cognition by studying neurodynamics and circuit modeling associated with statistical learning (SL), which shares similar neural mechanisms to the sensory auditory chirp (Aim 2). Third, the investigators will use individualized closed-loop alpha auditory entrainment (AAE) to attempt the normalization of neural signatures of the sensory auditory chirp and SL tasks (Aim 3). Aim 1 and 2 findings will provide critical data to optimize closed-loop parameters of AAE to serve as a "bottom- up" neural probe to understand the mechanics of disorder-relevant circuit activity through perturbation of thalamocortical drive. Ascertaining the mechanisms underlying these alterations would have a high clinical impact, especially to enhance early intervention to alter the trajectory of intellectual development in which no definitive treatments are available.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Fragile X Syndrome with full FMR1 mutations (\>200 CGG repeats; at least partial FMR1 gene methylation)
Other: Alpha Auditory Entrainment · Other: Sham
Age and sex-matched with FXS cohort
Other: Alpha Auditory Entrainment · Other: Sham
Subjects with neither disorder who have met normal developmental milestones
Other: Alpha Auditory Entrainment · Other: Sham
Alpha Brainwave Entrainment (AAE) stimulus: starts at high theta range (7-Hz) through high alpha (13-Hz) in 2 Hz steps on a 500 Hz sine carrier tone Target frequency: 10 Hz Delivery: headphones/speakers
Also known as: Alpha Brainwave Entrainment, Alpha Binaural Beats, Pulsed Sound Stimulation, Sonic Entrainment
Sham stimulus: carrier tone alone Target frequency: N/A Delivery: headphones/speakers
Alpha auditory entrainment versus sham effect on Word Learning Index during the Statistical Learning Passive Task.
The Statistical Learning Passive Task uses an EEG-based measure of neural entrainment that uses inter-trial coherence (ITC) to calculate Word Learning Index (WLI). Patterns of EEG phase-locking, corresponding to a shift in processing from raw syllable units to cohesive words, reflect gradual statistical learning in the brain. The WLI effect can be quantified by creating a ratio of the inter-trail coherence for words versus syllables, as follows: WLI = Inter-trial Coherence word rate / Inter-trial Coherence syllable rate A higher WLI indicates a relatively stronger response to tri-syllabic nonwords compared to raw syllables, reflecting stronger word segmentation due to statistical learning.
Time frame: 1 week
Alpha auditory entrainment versus sham effect on the Behavior Learning Effect during the Statistical Learning Active Task.
The Active SL Task based measure uses reaction time to estimate a behavioral measure of SL, the Behavioral Learning Effect BLE. BLE values indicate greater proportional facilitation to predictable words in the stream, indicative of stronger SL at the individual level. The Behavioral Learning effect is quantified as follows: BLE (in ms) = (Reaction time target syllable position 1)-(Reaction time target syllable position 3) Larger BLE values indicate greater proportional facilitation to predictable words in the stream, indicative of stronger SL at the individual level.
Time frame: 1 week
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — all collected, deidentified IPD
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: upon publication of results
Access criteria: Research data gathered as part of this study may be shared and provided to other investigators affiliated with the Neurobehavioral and Neurology Research Teams at CCHMC for the purpose of data sharing. If participants are enrolled in multiple studies, their research data will be shared across studies to reduce participant burden and avoid duplication of procedures. Only investigators/research team affiliated with CCHMC will have access to secured files and/or research data and will be well-informed regarding the protection of participants' rights to confidentiality.
Started May 2023 (actual). Primary completion is estimated for May 2027, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital Medical Center, Cincinnati →